Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 22.
doi: 10.1111/epi.18605. Online ahead of print.

Standard complete blood count to predict long-term outcomes in febrile infection-related epilepsy syndrome (FIRES): A multicenter study

Martin Guillemaud  1 , Aurélie Hanin  1   2   3   4 , James J Riviello  5 , Mario Chavez  1 , Ayush Batra  6 , Megan Berry  7 , Francesca Bisulli  8   9 , Carlos Castillo-Pinto  10 , Carla Cobos-Hernandez  11 , Sophie Demeret  12 , Krista Eschbach  11 , Raquel Farias-Moeller  13 , Madeline Fields  14 , Nicolas Gaspard  4   15 , Elizabeth E Gerard  6 , Teneille E Gofton  16 , Margaret T Gopaul  4 , Matthew D Gruen  4 , Anthony D Jimenez  4 , Karnig Kazazian  16 , Minjee Kim  6 , Marwa Mansour  17 , Lara Marcuse  14 , Clémence Marois  12 , Mikaela Morales  10 , Lorenzo Muccioli  8   9 , Elena Pasini  8 , Michelle M Pham  18 , Santiago Philibert Rosas  7 , Aaron F Struck  7 , Nathan Torcida  15 , Mark S Wainwright  10 , Ji Yeoun Yoo  14 , Eyal Muscal  5   19 , Vincent Navarro  1   20 , Lawrence J Hirsch  4 , Yichen Lai  17
Affiliations

Standard complete blood count to predict long-term outcomes in febrile infection-related epilepsy syndrome (FIRES): A multicenter study

Martin Guillemaud et al. Epilepsia. .

Abstract

Objective: We investigated whether complete blood count (CBC) analyses during intensive care unit stay could predict 12-month outcomes in patients with cryptogenic febrile infection-related epilepsy syndrome (FIRES), a subset of new-onset refractory status epilepticus (NORSE).

Methods: Outcomes at 12 months were classified as "unfavorable" (Glasgow Outcome Score [GOS] 1-3) or "favorable" (GOS 4-5). Demographic, clinical, and serial CBC data were collected across treatment phases: (1) no immunotherapy (before initiation or no treatment), (2) first-line immunotherapy, and (3) second-line immunotherapy. For each treatment phase, predictive models stratified outcomes based on CBC features using decision tree regression, with separate models for adults and children. Model performance was tested using a leave-one-patient-out approach.

Results: We studied 63 patients (34 adults, 29 children) from 12 centers. Unfavorable outcomes occurred in 18 adults and 12 children. Children were more likely to receive second-line immunotherapy. We analyzed 1530 CBCs (adults: 997 CBCs, including 539 for unfavorable outcomes; children: 533 CBCs, including 415 for unfavorable outcomes). Subgroup analyses revealed differences in CBC levels according to the outcomes and the treatment received. Adults with unfavorable outcomes notably had higher neutrophil-to-lymphocyte ratios (NLRs) and monocyte-to-lymphocyte ratios (MLRs), whereas children with unfavorable outcomes had higher red cell distribution width. NLRs and MLRs increased when CBCs were collected after the initiation of immunotherapy for both adults and children. The variables of interest differed in the different predictive models but always included the proportion of at least one subtype of leukocyte. Prediction accuracy with our models was higher in children (87% overall, with the best performance in no-treatment and first-line phases) than in adults (83% overall, with the best performance during/after the initiation of second-line).

Significance: Findings suggest the potential for standard CBCs to serve as a rapid, accessible tool for early prognostication in cryptogenic FIRES, particularly in children.

Keywords: FIRES; NORSE; complete blood count; outcomes.

PubMed Disclaimer

References

REFERENCES

    1. Clarkson BDS, LaFrance‐Corey RG, Kahoud RJ, Farias‐Moeller R, Payne ET, Howe CL. Functional deficiency in endogenous interleukin‐1 receptor antagonist in patients with febrile infection‐related epilepsy syndrome. Ann Neurol. 2019;85(4):526–537.
    1. Kenney‐Jung DL, Vezzani A, Kahoud RJ, LaFrance‐Corey RG, Ho M‐L, Muskardin TW, et al. Febrile infection‐related epilepsy syndrome treated with anakinra. Ann Neurol. 2016;80(6):939–945.
    1. Jun J‐S, Lee S‐T, Kim R, Chu K, Lee SK. Tocilizumab treatment for new onset refractory status epilepticus. Ann Neurol. 2018;84(6):940–945.
    1. Horino A, Kuki I, Inoue T, Nukui M, Okazaki S, Kawawaki H, et al. Intrathecal dexamethasone therapy for febrile infection‐related epilepsy syndrome. Ann Clin Transl Neurol. 2021;8(3):645–655.
    1. Sakuma H, Tanuma N, Kuki I, Takahashi Y, Shiomi M, Hayashi M. Intrathecal overproduction of proinflammatory cytokines and chemokines in febrile infection‐related refractory status epilepticus. J Neurol Neurosurg Psychiatry. 2015;86(7):820–822.

LinkOut - more resources